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Abstract
Objective: Long-term health-related quality of life (HRQoL) was determined for patients admitted to the haematology ward
who needed intensive care treatment (H-IC+) and compared with those who did not (H-IC2) as well as with that for patients
admitted to the general ICU (nH-IC+).
Methods: A cross-sectional study was carried out median 18 months after admission by employing the short form-36,
checklist for individual strength, cognitive failure questionnaire and hospital anxiety and depression scale.
Results: 27 (79%) of the 34 H-IC+ patients approached, and 93 (85%) of the 109 H-IC2 patients approached replied. Data
were adjusted for relevant covariates and matched with those of 149 patients in the general ICU. Apart from the lower role-
physical functioning score for H-IC+ (P= 0.04) no other differences were found between H-IC+ and H-IC2. Groups H-IC+ and
nH-IC+ evaluated their HRQoL on SF-36 similarly, except for the lower aggregated physical component summary (PCS) for
H-IC+ (P,0.0001). After adjusting for PCS, no significant differences in CIS, CFQ and HADS were observed between the
groups.
Conclusions: Eighteen months after admission, patients treated for haematological malignancies reported similar HRQoL,
whether or not they had received intensive care treatment, but reported a lower PCS than those of patients in the general
ICU. Hence, there is no reason to assume that admission to the ICU has a negative impact on long-term HRQoL, so this
should not affect the decision whether or not to transfer patients with haematological malignancies to the ICU.
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Introduction
Survivors of critical illnesses are frequently left with a legacy of
long-term physical, neuropsychiatric and quality of life impair-
ments [1]. Patients who survive critical illness report significantly
lower health-related quality of life (HRQoL) after a year compared
to their well being before intensive care unit (ICU) admission as
well as that of the general population [2,3].
Treatment of patients with haematological malignancies has
become increasingly intensive consisting of several cycles of high-
dose chemotherapy, often followed by an allogeneic or autologous
hematopoietic stem cell transplant (HSCT). As a consequence,
these patients are at risk for critical illness. In the last decade the
contribution of ICU’s during treatment of haematological
malignancies has significantly improved [4]. ICU physicians have
been successful in improving survival beyond the acute stage of
critical illness by emphasizing the importance of early recognition
of clinical deterioration. Improved insight into the treatment of
sepsis and the introduction of non-invasive and protective positive
pressure ventilation strategies to overcome respiratory failure have
also played a role [5–7].
Long-term HRQoL of patients being treated for haematological
malignancies is relevant to assist physicians in their decision
whether or not to admit the patient to the ICU. Recent reports are
conflicting, as both persistent impaired HRQoL [3] and restore-
ment of HRQoL 90 days following ICU discharge in 80% of
survivors was determined [8]. No comparisons to haematological
patients that did not need intensive care and non-haematological
ICU patients were made.
With the current study we aim to determine long-term self-
reported HRQoL, including fatigue, cognitive functioning, anxiety
and depression of patients being treated for a haematological
disease who were given intensive care and to compare these
HRQoL scores with those of haematological patients who did not
receive intensive care as well as those of a group of general medical
ICU patients.
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Patients and Methods
Ethics statement
The Committee on Research Involving Human Subjects
(Arnhem-Nijmegen region CMO) approved the study protocol
(study number 2010/306) and waived the need for informed
consent since the objective of this study was to evaluate regular
patient care. Patient privacy was guaranteed as all data were
anonimised and evaluated in a blinded fashion.
Patients with haematological disease
All consecutive patients who were admitted for five days or
more to our tertiary care medical centre for treatment of a
haematological malignancy during a 1 year period were eligible
for the survey. Survivors were divided into two groups depending
upon whether or not they had been admitted to the ICU. A
HRQoL questionnaire was sent to them a median of 18 months
after admission (range of 12–24 months). This same procedure was
carried out twice on two consecutive years for those who were
admitted to the ICU during treatment in order to enlarge the
group (Figure 1). Non-responders were sent a reminder six weeks
later. Demographic and medical data were collected from the
patient files.
General ICU patients
Data of general ICU patients without a haematological
malignancy were retrieved from a group of 401 medical admission
patients between February 2008 and February 2009. These
patients were approached in a similar way as the haematological
groups and non-responders were sent a reminder six weeks later. A
total of 285 (71%) patients responded and 149 of these were
meticulously matched with their haematological ICU counterparts
for age, gender, APACHE-II score and ICU length of stay. The
methods of HRQoL measurement for this group was similar to
that for the haematological groups [9].
ICU characteristics
There was no explicit ICU admission policy at the time and the
decision to admit a patient to one of the level 3 general ICUs was
made by the senior haematologists and intensivists. ICU charac-
teristics and reason for ICU admission were extracted from patient
files.
Questionnaires
The following four different validated questionnaires were used
to measure health related quality of life. The short form-36 (SF-36)
contains 8 multi-item dimensions covering various aspects of
physical, social, emotional and mental health. Missing values were
imputed according to the health survey manual [10] and
aggregated summary scores were expressed in a physical
Figure 1. Flowchart on inclusion. Enclosed as file ‘figure 1’.
doi:10.1371/journal.pone.0087779.g001
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component summary (PCS) and a mental component summary
(MCS) ranging between 0–100, a higher score indicating a higher
level of functioning [11]. The shortlist of the checklist individual
strength-fatigue (CIS-fatigue), consisting of 8 questions scoring on
a 7-point Likert scale. The range of CIS-fatigue is 8–56, a higher
score indicating more pronounced fatigue [12]. The validated
Dutch translation of the cognitive failure questionnaire (CFQ) is
self-reported [13] and consists of 25 questions on memory,
distractibility, social blunders and names [14]. Each question was
scored on a 5-point Likert scale. The total score on the CFQ
ranges from 0–100, a higher score indicating more self-reported
cognitive impairment. The hospital anxiety and depression scale
(HADS) is a 14-item self-reporting measure of psychological
distress and widely used for cancer patients [15]. The HADS has
two subscales (anxiety and depression), each ranging from 0 to 21.
Each item is rated on a scale from 0 (‘not at all’) to 3 (‘very much’)
and higher scores indicate more anxiety and depression [16]. The
non-haematological ICU patients did not receive the HADS
questionnaire.
Thus, our self-reported HRQoL survey consisted of a total of 83
questions. The data obtained were recoded and subsequently
scored according to their manuals. To guarantee patients’ privacy,
the survey was sent out anonymously and assigned a number. This
allowed the primary and supervising investigator to match the
returned survey with the patient’s registry number held in a
separate confidential database.
Statistical analysis
All data were analyzed using SPSS version 20.0.0.1 (SPSS,
Chicago, IL). The t-test was used for normally distributed
variables, Mann-Whitney U test for variables that were not
normally distributed and the Chi-square test for binary variables.
Correlations between physical component summary and mental
component summary were determined using Pearson’s correlation
coefficient.
Significant differences between the variables were considered as
covariates. Since data were not normally distributed, a log-
transformation was performed in order to perform a multivariate
analysis of covariance. Since this was an exploratory study, and to
increase sensitivity for putative differences between the groups,
there was no correction for multiple testing. Statistical significance
was defined as a P-value ,0.05.
Results
Characteristics of patients with haematological disease
In total 573 patients were eligible, of which 143 patients could
be approached for the study (Figure 1). Mortality during this long-
term follow-up was significantly higher for H-IC+ (108/142, 76%),
compared to group H-IC2 (234/431, 45%) (P,0.0001).
In H-IC+ 34 questionnaires were sent out and 27 questionnaires
(79%) were completed, median 15 months [Inter Quartile Range
(IQR) 12–20] following admission. The mean APACHE-II score
was 18.569.2 (Table 1). In total 109 questionnaires were sent to
haematological patients that did not need ICU treatment and 93
questionnaires (85%) were completed, median 16 months [IQR
13–20] following admission. In both groups the proportion of
patients admitted for an allogeneic or autologous hematopoietic
stem cell transplant, chemotherapy or complications were
comparable. No significant differences in demographic character-
istics were found between the groups, except for the proportion of
acute leukaemia/MDS which was higher in H-IC+ (P=0.008,
Table 1. Demographic characteristics of responding patients with and without ICU admission.
Haematology patients with ICU
admission (N=27)
Haematology patients without ICU
admission (N=93) General ICU patients (N=149)
Age 52.8614.2 53.5613.3 56.9616.7
Gender (M) 17 (63%) 54 (58%) 72 (48%)
APACHE-II score 18.569.2 n.a. 19.065.4
LOS-Hospital (days) 33 [25–42]a 21 [11–27] 18 [10–37]b
LOS-ICU (days) 5 [2–10] n.a. 4 [2–10]
Diagnosis (N,%):
Acute leukaemia and MDS (AML,
ALL and MDS)
13 (48)a 20 (22)
Malignant lymphoma (NHL,
M. Hodgkin and M. Waldenstro¨m)
7 (26) 28 (30) n.a.
Multiple myeloma 4 (15) 28 (30)
Chronic leukaemia (CML and CLL) 1 (4) 13 (14)
Other 2 (7) 4 (4)
Hospital admission reason (N,%):
Allogeneic HSCT (SIB, VUD and SIB-RIC) 6 (22) 15 (16)
Autologous HSCT 4 (15) 29 (31) n.a
Non-HSCT chemotherapy 7 (26) 16 (17)
Complications (after non-HSCT
chemotherapy, after HSCT or without
preceding treatment)
10 (37) 33 (36)
Data are expressed as mean with (6) standard deviation or median with IQR unless other reported.
astatistically significantly different (P,0.05) compared with haematology patients without ICU admission.
bstatistically significantly different (P,0.05) compared with haematology patients with ICU admission.
doi:10.1371/journal.pone.0087779.t001
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Table 1). Hospital length of stay was significantly longer for H-IC+
(median 33 days [interquartile range 25–42]), compared to H-IC2
(21 days [11–27], P,0.001) or nH-IC+ (18 days [10–37],
P,0.001).
Characteristics of general ICU patients
In total 149 general ICU patients were matched with the
haematological patients that needed ICU treatment. Twenty-six
(17%) patients had a proven infection of which 18 patients had a
sepsis. The mean APACHE-II score was 1965.4 (Table 1).
Health Related Quality of Life Questionnaires
Haematological diagnosis and length of hospital stay served as
covariates for the SF-36 analysis and were complemented by the
Physical Component Summary as covariate for the analyses of
CIS-fatigue, CFQ and HADS differences between the groups.
Short Form-36
H-IC+ respondents reported a similar HR-QoL to H-IC2 in
almost all domains of the SF-36, with the exception of a difference
in the Role Physical dimension namely, H-IC+ reported more
problems with work or other daily activities as a result of physical
health (P=0.04) (Table 2). Compared to nH-IC+, H-IC+ reported
a lower score on the resulting aggregated PCS (P,0.001), while
the aggregated MCS was not different between the groups. The
results for the other domains of the SF-36 were similar (Figure 2).
No correlations were found between the PCS and MCS as
Pearson correlation coefficients were r = 0.22 for H-IC+ (P=0.30),
r = 0.14 for H-IC2 (P=0.90) and r = 0.10 for nH-IC+ (P=0.28).
Both H-IC+ and H-IC2 survivors evaluated their HR-QoL on
several domains of the SF-36 worse compared with the age-
adjusted general Dutch population of which the reference values
are reflected in Table 2.
Checklist individual strength-fatigue
No significant differences between H-IC+ and H-IC2 or H-
IC+ and nH-IC+ were found for self evaluated fatigue score after
adjusting for covariates (Table 3).
Cognitive Failure Questionnaire
Cognitive failure was similar after adjusting for covariates on all
measured cognitive dimensions between H-IC+ and H-IC2. The
overall cognitive functioning tended to be better for H-IC+ than
for nH-IC+ (P=0.06) (Table 3).
Hospital anxiety and depression scale
Adjusted results showed no differences in anxiety or depression
between H-IC+ and H-IC2 a median 16 months after admission
(Table 3). For nH-IC+ were no data available.
Discussion
The main finding of the present study is that a median of 18
months after admission to an ICU, patients who had been treated
for a haematological disease and were admitted to an ICU
experienced only a lower quality in the physical aspects of their life
compared with those admitted to the ICU without a haematolog-
ical disease. Patients treated for a haematological malignancy who
had not been admitted to the ICU reported only better role-
physical functioning. In addition, the long-term health-related
mental quality of life as well as fatigue, cognition, anxiety and
depression was similar between the groups. As we did not correct
for multiple testing, the small differences between groups appear
not to be of clinical relevance.
It is likely that complications following haematological treat-
ment and HSCT both influence physical functioning and the
ability to perform social activities [17].The fact that the only
differences in HRQoL concerned physical aspects may have been
due to complications during haematological treatment that
necessitated the ICU admission [18].
The recent publication by Oeyen et al [3], in which long-term
quality of life was prospectively assessed in haematological patients
1 year after ICU discharge, reports poor QoL outcomes at 1 year,
particularly for the haematological subgroup. However, physical
complications of haematological treatment are likely to be related
to the severity of the underlying disease, its treatment and need for
more rigorous ICU therapy and seem to require longer
rehabilitation periods than 1 year and also exceeds the median
18 months reported in our current study. This is what may
distinguish patients with haematological malignancies from
general ICU patients and seems confirmed in a recent study
[19] where the PCS at 5 years post-HSCT was similar to those of
nH-IC+ in our study at 18 months. These studies represent the
limited amount of evidence available on long-term HR-QoL. ICU
survival and subsequent hospital survival have improved the past
decade to such extent that long-term HR-QoL becomes more
important in the decision to admit or not admit a critically ill
patient to the ICU. Our finding that long-term HRQoL is
comparable in haematological patients with and without an ICU
admission is of relevance. This emphasizes the need for more long-
term HR-QoL studies that may correct the assumption that
patients should not be admitted to the ICU assuming that the
long-term outcome will be poor.
The absence of any correlation between the physical and mental
component summary scores in all subgroups is remarkable, but has
been described earlier [20]. Curbow et al found that recipients of
stem cell transplant reported more positive changes in relationship
and existential/psychological domains and more negative changes
in the physical health domain [21]. The same has been observed
for survivors of meningococcal septic shock, who, despite suffering
from severe skin scarring or extensive amputation, did not show
more behavioural problems as predictor for poorer HRQoL, nor
more cognitive dysfunction [22]. In fact, cancer survivorship is a
well-recognized phenomenon in which patients confronted with a
life threatening illness are faced with the necessity to accommodate
to the disease leading to acceptance of and adjustment to the
illness [23]. These patients might experience a similar condition
higher than they would have if they had not experienced a serious
illness [24].
The strength of the current study is the explorative character
and clinical relevance of the results, comparing H-IC+ with both
H-IC2 and nH-IC+ patients. However, there are also relevant
limitations that need to be addressed. Despite the high response
rate on the questionnaires, the possibility of non-response bias [25]
cannot ruled out. Also the study was undertaken in such a specific
population that only a relatively small number of patients could be
analyzed. As a consequence, it was not feasible to analyze data for
the subgroup of allogeneic HSCT recipients who may be more
likely to experience treatment-related physical complications such
as graft-versus-host-disease (GvHD), that are known to influence
HRQoL [26]. The type of conditioning regimen, female gender,
younger age, inadequate social support and pre-transplant
psychological distress have also been reported to be predictors
for a poorer HRQoL following HSCT [27]. Disease status and
performance status preceding intensive treatment for haemato-
logical diseases can usually be assumed to be good to be qualified,
HRQoL following Haematological Treatment
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but further baseline characteristics such as social status and pre-
existing distress could not be considered as the study was
retrospective. Moreover, we only measured HRQoL once where
serial measures would have been more informative on changes
over time. Nevertheless, patients with haematological malignancies
form a unique subpopulation of ICU patients and our cohort
represents one of the largest with long-term HRQoL evaluations
currently available. This is increasingly becoming considered to
represent a relevant measure of outcome.
Figure 2. Spider graph of the Short Form-36 measurements median 16 months after ICU discharge, adjusted for covariates. Enclosed
as file ‘figure 2’.
doi:10.1371/journal.pone.0087779.g002
Table 2. Results of Short Form-36 measurements median 16 months after ICU discharge adjusted for covariates.
SF-36{
Haematology patients
with ICU admission
(N=27)
Haematology patients
without ICU admission
(N=93)
General ICU patients
(N=149)
General Population
Subgroup Age 41–60 [11]
(reference values)
Physical Functioning 52.9627.6 64.6627.6 52.2632.0 84.0619.6
Role-Physical 35.2635.5a 40.3642.8 38.0641.1 74.5636.8
Bodily Pain 71.8625.1 74.1624.5 68.7628.5 71.8624.1
General Health 45.6621.5 46.3623.4 48.8622.0 69.7620.6
Social Functioning 72.7626.4 66.1626.3 67.0625.8 83.5622.1
Vitality 56.0616.7 54.7620.5 54.3619.6 68.6620.2
Role-Emotional 65.4640.8 76.0637.9 61.0643.2 81.6633.2
Mental Health 75.4619.0 74.0617.7 68.8619.2 75.6618.5
Physical Component Summary 36.768.5 39.1611.6 48.069.7b n.a.
Mental Component Summary 49.6611.2 48.4610.7 47.969.8 n.a.
Data are expressed as mean with standard deviation (6).
{adjusted for diagnose acute leukaemia and MDS and LOS-in hospital using log transformed data (not shown).
astatistically significantly different (P,0.05) compared with haematology patients without ICU admission.
bstatistically significantly different (P,0.05) compared with haematology patients with ICU admission.
doi:10.1371/journal.pone.0087779.t002
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Conclusions
In conclusion, there is no support for the assumption that
patients undergoing treatment for a haematological malignancy
who are admitted to the ICU have a worse long-term HRQoL
than those who are not. Therefore the risk of a poorer long term
quality of life should no longer be used as an argument not to
admit these patients to the ICU.
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